// App-Quantinova.ai

O23 : Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes

Researchers

Presenter

  • Christopher J Edwards

Principal Investigators

  • Andrew J Bradley

  • Mani H Nassab

  • Burkhard Mller

  • Klaus P Machold

  • Christophe Sapin

  • Roberto Ranza

  • Soyi L Leage

Medical Centers

  • NIHR Clinical research Facility, University Hospital Southampton, Southampton, UNITED KINGDOM

  • Eli Lilly and Company, Indianapolis, IN

  • Department of Rheumatology, Immunology and Allergology, Inselspital – University Hospital Bern, Bern, SWITZERLAND

  • Department of Internal Medicine, Clinic of rheumatology, Medical University - Sofia

  • Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, BRAZIL

Locations

  • United Kingdom

  • United States

  • Switzerland

  • Brazil

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • Prostate specific antigen

  • Albumin/creatinine

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03151551

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved